Risk‐mitigating behaviours in people with inflammatory skin and joint disease during the COVID‐19 pandemic differ by treatment type: a cross‐sectional patient survey*

Registry data suggest that people with immune‐mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID‐19) outcomes compared with patients receiving no systemic treatments.

[1]  M. Kappelman,et al.  Reply , 2021, Gastroenterology.

[2]  S. Feldman,et al.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study , 2020, Journal of Allergy and Clinical Immunology.

[3]  K. Bhaskaran,et al.  Ethnic differences in COVID-19 infection, hospitalisation, and mortality: an OpenSAFELY analysis of 17 million adults in England , 2020, medRxiv.

[4]  M. Feldmann,et al.  Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment , 2020, The Lancet Rheumatology.

[5]  E. Broadbent,et al.  Mental health in the UK during the COVID-19 pandemic: cross-sectional analyses from a community cohort study , 2020, BMJ Open.

[6]  G. Argenziano,et al.  Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis , 2020, PloS one.

[7]  N. Barkham,et al.  COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre , 2020, Annals of the Rheumatic Diseases.

[8]  S. Kraus,et al.  Predictors of COVID-19 voluntary compliance behaviors: An international investigation , 2020, Global Transitions.

[9]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[10]  V. Soriano,et al.  Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity , 2020, International Journal of Infectious Diseases.

[11]  Fayzan F. Chaudhry,et al.  SARS-CoV-2 viral load predicts COVID-19 mortality , 2020, The Lancet Respiratory Medicine.

[12]  I. Tan,et al.  FRI0520 HOSPITALIZATIONS FOR HEMATOLOGICAL MALIGNANCIES WITH RHEUMATIC DISEASES: A NATIONAL INPATIENT SAMPLE ANALYSIS OF TEN YEARS (2005-2014) , 2020, Annals of the Rheumatic Diseases.

[13]  S. Ng,et al.  Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry , 2020, Gastroenterology.

[14]  L. Trupin,et al.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.

[15]  B. Griffiths,et al.  Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic. , 2020, Clinical medicine.

[16]  T. Liang,et al.  Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study , 2020, BMJ.

[17]  B. Pfefferbaum,et al.  Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[18]  Zhicheng Wang,et al.  Combating COVID-19: health equity matters , 2020, Nature Medicine.

[19]  G. Onder,et al.  Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. , 2020, JAMA.

[20]  K. Kim,et al.  What Is COVID-19? , 2020, Frontiers for Young Minds.

[21]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[22]  C. Siegel,et al.  Patients' Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. , 2019, Inflammatory bowel diseases.

[23]  M. Lebwohl,et al.  Biological treatment for psoriasis and the risk of herpes zoster: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) , 2019, The Journal of dermatological treatment.

[24]  Richard Inger,et al.  A brief introduction to mixed effects modelling and multi-model inference in ecology , 2018, PeerJ.

[25]  J. Galloway,et al.  Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2018, Annals of the rheumatic diseases.

[26]  M. Dougados,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[27]  M. Lebwohl,et al.  Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). , 2015, JAMA dermatology.

[28]  W. Dixon,et al.  O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor-α Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis , 2015 .

[29]  D. M. van der Heijde,et al.  Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis , 2014, Annals of the rheumatic diseases.

[30]  Myrna M. Khan,et al.  A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers , 2013, BMJ Open.

[31]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[32]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.